Saniona inleder klinisk prövning i Fas 1 med SAN711
June 30, 2021 06:45 ET
|
Saniona AB
PRESSMEDDELANDE 30 juni 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att den första patienten har doserats i en...
Saniona Initiates Phase 1 Clinical Trial of SAN711
June 30, 2021 06:45 ET
|
Saniona AB
PRESS RELEASE June 30, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has dosed the first patient in a Phase 1 clinical...
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
June 28, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for...
Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease
June 25, 2021 02:00 ET
|
Orphalan
Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease JUNE 25, 2021 - ORPHAN DISEASES — CHELATE trial confirmed trientine...
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
June 22, 2021 07:00 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for...
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
June 17, 2021 07:00 ET
|
Imara, Inc.
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET
|
Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Saniona presenterar prekliniska data för SAN711 vid European Academy of Neurologys sjunde kongress
June 08, 2021 08:00 ET
|
Saniona AB
PRESSMEDDELANDE 8 juni 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att prekliniska data för SAN711 i en modell av...
Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology
June 08, 2021 08:00 ET
|
Saniona AB
PRESS RELEASE June 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it will present preclinical data on SAN711 in a model of facial...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET
|
Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...